Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 8/20 | 0.67 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.67 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.67 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.67 |
| ▸ | GPR52 | Q9Y2T5 | 8/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2074226 | 0.85 | PIK3CD (0.65) | PIK3CDPIK3CAPIK3CGPIK3CBGPR52 | |
| SCHEMBL48693 | 0.83 | PIK3CD (0.65) | PIK3CDPIK3CAPIK3CGPIK3CBGPR52 | |
| SCHEMBL4033143 | 0.82 | PIK3CD (0.65) | PIK3CDPIK3CAPIK3CGPIK3CBGPR52 | |
| SCHEMBL3143365 | 0.80 | PIK3CD (0.53) | PIK3CDPIK3CAPIK3CGPIK3CBGPR52 | |
| SCHEMBL48634 | 0.80 | PIK3CG (1.00) | PIK3CDPIK3CAPIK3CGPIK3CB | |
| SCHEMBL4201345 | 0.80 | PIK3CD (0.67) | PIK3CDPIK3CAPIK3CGPIK3CBGPR52 | |
| SCHEMBL27637489 | 0.75 | PIK3CD (0.61) | PIK3CDPIK3CAPIK3CGPIK3CBGPR52 | |
| SCHEMBL48770 | 0.75 | PIK3CD (0.75) | PIK3CDPIK3CAPIK3CGPIK3CB | |
| SCHEMBL5804528 | 0.75 | PIK3CD (0.68) | PIK3CDPIK3CAPIK3CGPIK3CB | |
| SCHEMBL5048901 | 0.75 | GPR52 (0.56) | GPR52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280871-A1 | 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases | NOVARTIS AG (CH) | 2008-11-13 | — | — | US | claimed |
| CN-1838953-B | Phosphatidylinositol 3-kinase (PI) for the treatment of inflammatory airway diseases3) Inhibitor 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives | NOVARTIS AG | 2011-02-02 | — | — | CN | disclosed |
| EP-1689391-B1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES | NOVARTIS AG (CH) | 2009-04-22 | — | — | EP | disclosed |
| US-20080280871-A1 | 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases | NOVARTIS AG (CH) | 2008-11-13 | — | — | US | disclosed |
| US-20080021019-A1 | immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease; substituted pyrazine compounds | SCHERING CORPORATION | 2008-01-24 | — | — | US | disclosed |
| CN-1838953-A | Phosphatidylinositol 3-kinase (PI3) inhibitor 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives for the treatment of inflammatory airway diseases | NOVARTIS AG (CH) | 2006-09-27 | — | — | CN | disclosed |
| EP-1689391-A2 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES | Novartis AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005021519-A2 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES | NOVARTIS AG (CH) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280871-A1 | 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases | PI4KA, IP6K3, PHOSPHO1 | PIK3CD 26/4885PIK3CA 16/4885PIK3CG 23/4885 |
| US-20080021019-A1 | immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease; substituted pyrazine compounds | BRCA1, PDK2, PDK1 | PIK3CD 197/4885PIK3CA 127/4885PIK3CG 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.